Patient Voice

823 Living Donation: The Donors and Recipient Perspectives
Maria E. Díaz-González de Ferris, Lourdes M. Díaz-González, and Michael Ted Ferris
See related editorial and article on pages 831 and 916.

Editorials

825 Ptolemy and Copernicus Revisited: The Complex Interplay between the Kidneys and Heart Failure
Steven G. Coca
See related article on page 833.

829 Race in America: What Does It Mean for Diabetes and CKD?
Katherine R. Tuttle
See related article on page 884.

831 Donor Outcomes: Why We Need to Listen
Milda R. Saunders and Michelle A. Josephson
See related Patient Voice and article on pages 823 and 916.

Original Articles

Acute Kidney Injury and ICU Nephrology

833 Acute Kidney Injury and Risk of Heart Failure and Atherosclerotic Events
Alan S. Go, Chi-yuan Hsu, Jingrong Yang, Thida C. Tan, Sijie Zheng, Juan D. Ordonez, and Kathleen D. Liu
See related editorial on page 825.

842 Identification of Patients Expected to Benefit from Electronic Alerts for Acute Kidney Injury

Chronic Kidney Disease

850 Family Consultation to Reduce Early Hospital Readmissions among Patients with End Stage Kidney Disease: A Randomized Controlled Trial
Matthew J. Jasinski, Mark A. Lumley, Sandeep Soman, Jerry Yee, and Mark W. Ketterer

858 Sleep Duration and Health-Related Quality of Life in Predialysis CKD
Su-Ah Sung, Young Youl Hyun, Kyu Beck Lee, Hayne Cho Park, Wookyung Chung, Yeong Hoon Kim, Yong-Soo Kim, Sue Kyung Park, Kook-Hwan Oh, and Curie Ahn, on behalf of the KNOW-CKD Study Investigators

Clinical Nephrology

866 Changes in Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation: A Prospective Cohort Study
Sangeeta Hingorani, Emily Pao, Phil Stevenson, Gary Schoch, Benjamin L. Laskin, Ted Gooley, and George B. McDonald
Prevalence of Hypertension in Children with Early-Stage ADPKD

Incidence and Progression of Chronic Kidney Disease in Black and White Individuals with Type 2 Diabetes
Claire Gerber, Xuan Cai, Jungwha Lee, Timothy Craven, Julia Scialla, Nao Souma, Anand Srivastava, Rupal Mehta, Amanda Paluch, Alexander Hodakowski, Rebecca Frazier, Mercedes R. Carnethon, Myles Selig Wolf, and Tamara Isakova
See related editorial on page 829.

Association between Duration of Predialysis Care and Mortality after Dialysis Start

Concentrations of Trace Elements and Clinical Outcomes in Hemodialysis Patients: A Prospective Cohort Study

Identifying Outcomes that Are Important to Living Kidney Donors: A Nominal Group Technique Study
Camilla S. Hanson, Jeremy R. Chapman, John S. Gill, John Kanellis, Germaine Wong, Jonathan C. Craig, Armando Teixeira-Pinto, Steve J. Chadban, Amit X. Garg, Angélique F. Ralph, Jule Pinter, Joshua R. Lewis, and Allison Tong
See related Patient Voice and editorial on pages 823 and 831.

Comparative Effects of Cholecalciferol and Calcitriol on Circulating Markers of CKD Mineral Bone Disorder: A Randomized Clinical Trial
Leila R. Zelnick, Ian H. de Boer, Bryan R. Kestenbaum, Michel Chonchol, and Jessica Kendrick

Approach to the Young Patient with New-Onset Hypertension
Debbie L. Cohen and Raymond R. Townsend

A Patient with Hemolytic Uremic Syndrome and Kidney Failure
Joshua M. Thurman

A Case of Monoclonal Gammapathy of Renal Significance
Jonathan J. Hogan
Perspectives

940 The APOL1 Long-Term Kidney Transplantation Outcomes Network—APOLLO
Barry I. Freedman and Marva Moxey-Mims

943 Treatment of Depression in CKD Patients with an SSRI Why Things Don’t Always Turn Out as You Expect
Daniel Cukor and Paul L. Kimmel

946 Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing Platform
Hiddo J.L. Heerspink and Vlado Perkovic

949 Contrast-Induced Acute Kidney Injury in the PRESERVE Trial: Lessons Learned
Edward D. Siew and Kathleen D. Liu

Reviews

952 Parathyroidectomy in the Management of Secondary Hyperparathyroidism
Wei Ling Lau, Yoshitsugu Obi, and Kamyar Kalantar-Zadeh

962 Management of Osteoporosis in CKD
Pascale Khairallah and Thomas L. Nickolas

On the Cover

What’s the diagnosis?
A 25 year-old woman with SLE and antiphospholipid antibodies presented with altered mental status and AKI with serum creatinine (sCr) 1.8 mg/dL (baseline 0.5 mg/dL). Her BP was 119/79 mmHg. Urinalysis revealed 1847 RBC/hpf with RBC casts and 2.9 g of urine protein in 24 hours. C3 and C4 levels were both decreased. ANA, dsDNA, Smith, and RNP antibodies were positive. CT head demonstrated acute bilateral cerebellar infarcts. She was treated with iv heparin which was stopped 8 hours before kidney biopsy and restarted 24 hours afterward. Biopsy revealed RPS/ISN Class IV lupus nephritis. She was treated with methylprednisolone iv 1 g daily x 3 days followed by oral prednisone 60 mg daily, mycophenolate mofetil, lisinopril, and hydroxychloroquine. Her mental status significantly improved, and the sCr returned to 0.5 mg/dL within 8 days. By 1 month, sCr was 0.7 mg/dL with uPCR 0.77 g/g. Light microscopy showed mesangial matrix expansion, mesangial proliferation without endocapillary proliferation or crescents, and large immune deposits within the capillary walls (“wire loops”) (Figures 1 and 2). On immunofluorescence, diffuse, intense mesangial, capillary wall, and peritubular staining was present for C1q, IgG, IgA, IgM, C3, kappa, and lambda. Electron microscopy demonstrated subendothelial, intramembranous, subepithelial, mesangial, and peritubular capillary deposits with tubuloreticular inclusions (Figure 3).

A diagnosis of Class IV lupus nephritis can be made on the basis of different criteria, including the presence of extensive subendothelial immune deposits without endocapillary proliferation. Induction therapy for Class IV lupus includes a combination of glucocorticoids plus either IV cyclophosphamide or oral mycophenolate mofetil.

(Text and images provided by Sadichhya Lohani, MD, Mohamad Hanoun, MD, and C. John Sperati, MD, MHS, Johns Hopkins University, Department of Medicine, Division of Nephrology, Baltimore, Maryland)